公开(公告)号：US07133830B1

公开(公告)日：2006-11-07

申请号：US10007907

申请日：2001-11-13

Applicant: Thomas X. Hoban ,  David F. Craigmile, Jr. ,  Robert A. Dickel ,  Paul E. Grafing ,  Garrett M. Smith ,  Troy D. Smith ,  Cynthia L. Tarpo

Inventor： Thomas X. Hoban ,  David F. Craigmile, Jr. ,  Robert A. Dickel ,  Paul E. Grafing ,  Garrett M. Smith ,  Troy D. Smith ,  Cynthia L. Tarpo

IPC: G10L11/00 ,  H04M1/64 ,  H04M11/00

CPC classification number: H04M3/493

Abstract: A system and method for providing end user speech applications. The system is embodied in an application environment framework which exchanges messages with a target execution platform having a local call flow interpreter. A speech application comprised of a plurality of generic call flow objects is executed on the application environment framework. While the speech application executes, the application environment framework translates the generic call flow objects into platform specific call flow objects having a format recognizable by the local call flow interpreter of the target execution platform, formats the platform specific call flow objects into reply messages using a protocol recognizable by the target execution platform, and transmits the messages to the target execution platform. In this manner, a platform independent speech application effectively controls the operation of a platform dependent call flow interpreter to provide voice interaction with an end user.

Abstract translation: 一种用于提供终端用户语音应用的系统和方法。 该系统体现在与具有本地呼叫流解释器的目标执行平台交换消息的应用环境框架中。 在应用环境框架上执行由多个通用调用流对象组成的语音应用。 当语音应用程序执行时，应用程序环境框架将通用呼叫流对象转换为具有可由目标执行平台的本地呼叫流解释器识别的格式的特定于平台的呼叫流对象，将平台特定的呼叫流对象格式化为应答消息 协议可由目标执行平台识别，并将消息发送到目标执行平台。 以这种方式，独立于平台的语音应用程序有效地控制平台依赖的呼叫流解释器的操作以提供与最终用户的语音交互。

公开(公告)号：US09181266B2

公开(公告)日：2015-11-10

申请号：US14154161

申请日：2012-07-13

Applicant: Atwood Kim Cheung ,  Donovan Noel Chin ,  Jianmei Fan ,  Karen Marie Miller-Moslin ,  Michael David Shultz ,  Troy D Smith ,  Ronald Charles Tomlinson ,  Bakary-Barry Toure ,  Michael Scott Visser ,  Zhuoliang Chen

Inventor： Atwood Kim Cheung ,  Donovan Noel Chin ,  Jianmei Fan ,  Karen Marie Miller-Moslin ,  Michael David Shultz ,  Troy D Smith ,  Ronald Charles Tomlinson ,  Bakary-Barry Toure ,  Michael Scott Visser ,  Zhuoliang Chen

IPC: C07D401/12 ,  C07D409/14 ,  A61K31/453 ,  A61K31/4545 ,  C07D491/052 ,  C07D493/04

CPC classification number: C07D491/052 ,  A61K31/453 ,  A61K31/4545 ,  C07D401/12 ,  C07D409/14 ,  C07D493/04

Abstract: The present invention provides for compounds of formula (I): wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

Abstract translation: 本发明提供式（I）化合物：其中R1-R5和L在本文中定义。 本发明还提供药物组合物和组合物，其包含式（I）化合物以及使用这些化合物作为阻断酶抑制剂和用于治疗Wnt信号传导和阻断酶1和2信号传导相关疾病，其包括但是是 不限于癌症。

公开(公告)号：US20150025070A1

公开(公告)日：2015-01-22

申请号：US14154161

申请日：2012-07-13

Applicant: Atwood Kim Cheung ,  Donovan Noel Chin ,  Jianmei Fan ,  Karen Marie Miller-Moslin ,  Michael David Shultz ,  Troy D. Smith ,  Ronald Charles Tomlinson ,  Bakary-Barry Toure ,  Michael Scott Visser

Inventor： Atwood Kim Cheung ,  Donovan Noel Chin ,  Jianmei Fan ,  Karen Marie Miller-Moslin ,  Michael David Shultz ,  Troy D. Smith ,  Ronald Charles Tomlinson ,  Bakary-Barry Toure ,  Michael Scott Visser

IPC: C07D491/052 ,  C07D493/04 ,  C07D401/12

CPC classification number: C07D491/052 ,  A61K31/453 ,  A61K31/4545 ,  C07D401/12 ,  C07D409/14 ,  C07D493/04

Abstract: The present invention provides for compounds of formula (I): wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

Abstract translation: 本发明提供式（I）化合物：其中R1-R5和L在本文中定义。 本发明还提供药物组合物和组合物，其包含式（I）化合物以及使用这些化合物作为阻断酶抑制剂和用于治疗Wnt信号传导和阻断酶1和2信号传导相关疾病，其包括但是是 不限于癌症。

公开(公告)号：US08685980B2

公开(公告)日：2014-04-01

申请号：US13060154

申请日：2009-08-20

Applicant: Gilbert Ebai Besong ,  Christopher Thomas Brain ,  Clinton Alan Brooks ,  Miles Stuart Congreve ,  Claudio Dagostin ,  Guo He ,  Ying Hou ,  Steven Howard ,  Yue Li ,  Yipin Lu ,  Paul Neil Mortenson ,  Troy D. Smith ,  Moo Je Sung ,  Steven John Woodhead ,  Wojciech Wrona ,  Bharat Lagu

Inventor： Gilbert Ebai Besong ,  Christopher Thomas Brain ,  Clinton Alan Brooks ,  Miles Stuart Congreve ,  Claudio Dagostin ,  Guo He ,  Ying Hou ,  Steven Howard ,  Yue Li ,  Yipin Lu ,  Paul Neil Mortenson ,  Troy D. Smith ,  Moo Je Sung ,  Steven John Woodhead ,  Wojciech Wrona ,  Bharat Lagu

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P29/00

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D487/08

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract translation: 所公开的化合物涉及蛋白激酶相关病症的治疗和疗法。 还需要可用于治疗或预防或改善癌症，移植排斥和自身免疫性疾病的一种或多种症状的化合物。 此外，需要使用本文提供的化合物调节蛋白激酶如CDK1，CDK2，CDK4，CDK5，CDK6，CDK7，CDK8和CDK9的活性的方法。